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Abstracts 
1. Investigation into the Cellular Actions of Carnosine 
   Carnosine is a dipeptide composed of beta-alanine and histidine found exclusively in long-
lived animal tissues.  The cellular action of carnosine is still under extensive investigation; 
however, it has been proposed to have a role as an anti-oxidant and oxygen free radical 
scavenger, a physiological buffer, a heavy metal chelator, and has been implicated as an anti-
aging agent.2,4  Our lab has been studying the interaction between carnosine and heme by 
analyzing both the effect carnosine has on the glycation of the heme containing protein 
cytochrome c and the interaction of carnosine with free hemin.  We have observed that the 
addition of carnosine to glycated cytochrome c inhibits the formation of advanced glycation end 
product (AGE) structures.  We have also found that the addition of carnosine to a solution of free 
hemin drastically increases the solubility of hemin and causes a shift of the λmax in its UV-Vis 
absorbance profile.  We propose that carnosine is a natural intracellular heme chelator and that 
this interaction may act as a signal for cellular antioxidant processes.  We have designed an 
experiment to identify proteins capable of binding to carnosine and heme-chelated carnosine.  
Using mass spectral techniques, we were able to identify a protein isolated from kidney tissue 
lysates using carnosine affinity beads.  By identifying a carnosine protein binding partner, we 
gained a better understanding of the cellular action of carnosine that may eventually lead to the 
development of novel drugs for the treatment of a variety of diseases in which oxidative injury 
and cellular stress occurs. 
 
. 
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2. Proinsulin C-Peptide as an Active Biomolecule 
Proinsulin C-peptide was thought to be an inert species whose only purpose was for 
proper binding of insulin; however, now C-peptide is believed to be an important, biologically 
active molecule that can improve some of the complications associated with diabetes mellitus.  
In addition, type-1 patients who are able to maintain C-peptide levels have fewer complications 
and better glycemic control.  The goal of this project was to gain a better understanding of the 
biochemical mechanism of action of C-peptide by identifying cellular proteins in varying types 
of tissue cell lysates capable of binding to the proinsulin C-peptide. This experiment was 
performed via creating C-peptide affinity beads by attaching C-peptide to NHS magnetic beads 
via the peptide’s N-terminus. Once attached, cellular lysates of varying tissue types were 
incubated with the affinity beads. Any bound proteins are eluted, separated by reducing SDS-
PAGE, digested with trypsin, and identified via Protein Mass Fingerprint spectra obtained from 
the MALDI-TOF mass spectrometer. We were able to successfully identify several proteins from 
mouse kidney, liver, and heart tissue lysates that were isolated with the C-peptide affinity beads.  
The identification of these proteins has given us a better understanding of the purpose of C-
peptide in the body and how it is related to diabetes and other glucose related diseases.  We 
found that the C-peptide seems to play a role in increasing the antioxidant properties and glucose 
clearance rate within cells. 
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1. Investigation into the Cellular Action of Carnosine 
Introduction: 
    Carnosine is a dipeptide composed of beta-alanine and histidine (Figure 1.1).  Carnosine is 
found exclusively in animal tissue and is present in long-lived tissues, such as the brain and 
muscle, in surprisingly high concentrations (up to 20 mM).1  Carnosine has been implicated as an 
anti-aging agent because it can delay senescence in cultured human fibroblasts and can reverse 
the senescent phenotype in cultured human cells.2,3   The cellular action of carnosine is still 
under extensive investigation; however, it has been proposed to have a role as an anti-oxidant 
and oxygen free radical scavenger, a physiological buffer, a heavy metal chelator, and an 
immunostimulant.4  Carnosine has also been proposed to act as a naturally occurring anti-
glycating agent.5  Studies have shown that it can oppose the glycation of proteins and act to 
lessen some diabetic complications.  
 
Figure 1.1.  Structure of the dipeptide carnosine. 
 
Heme molecules consist of an iron atom held in a porphyrin (Figure 1.2). They are a 
major component in hemoglobin in red blood cells as well as myoglobin in the muscles and 
cytochrome c.6  Heme b, the most common isoform, is present in hemoglobin, myoglobin and 
cytochrome b.  Hemes are synthesized in the mitochondria and cytosol of immature red blood 
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cells.7  Free heme is toxic in that it catalyzes the oxidation, covalent cross-linking and aggregate 
formation of proteins, the formation of cytotoxic lipid peroxide via lipid peroxidation and 
damages DNA through oxidative stress.8  Heme toxicity can occur in a body with high levels of 
free heme in the blood plasma. This can be caused when a body absorbs exorbitant amounts of 
heme iron either from digesting animal meat or excessive intake of iron tablets. Genetic factors 
may predispose a body absorbing high amounts of heme. Hereditary hemochromatosis is the 
most common cause of heme toxicity. Some results of heme toxicity include heart problems, 
menstrual irregularity, chronic fatigue, joint pain, liver disease, diabetes, heart failure and cancer. 
Cells have methods to protect against heme toxicity such as through heme oxygenase-1 that 
catalyzes the degradation of heme in response to oxidative stress.9 
 
 
Figure 1.2.  Structure of the heme b molecule present in proteins including hemoglobin, 
myoglobin, and cytochrome b. 
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Our lab has been studying the interaction between carnosine and heme by analyzing both 
the effect carnosine has on the glycation of the heme containing protein hemoglobin and the 
interaction of carnosine with free hemin. Hemin is an iron containing porphyrin that holds a 
heme b with a chloride ligand. It is used medically to combat porphyria, a rare medical disorder 
in which porphyrins cannot be properly produced to form hemes in the body. We have found that 
the addition of carnosine to a solution of free hemin drastically increases the solubility of hemin 
and causes a shift of the λmax in its UV-Vis absorbance profile.  We propose that carnosine is a 
natural intracellular heme binder, and that this interaction may act as a signal for cellular 
antioxidant processes.  Perhaps carnosine or the heme-chelated carnosine may serve as a ligand 
for a nuclear receptor protein involved in the transcriptional regulation of a class of genes 
involved in a cellular protective/antioxidant pathway.  For example, heme-chelated carnosine 
may upregulate the transcription of heme oxygenase 1 (HO-1), the essential enzyme in heme 
catabolism.  Increased cellular HO-1 activity results in cytoprotection against oxidative injury 
and cellular stresses that would play a major role in cellular senescence. 
An oxidative environment in a cell means that the cell is overproducing oxidative species. 
This can cause oxidative stress on a system. This can be harmful to a body and cause toxic 
effects through the production of free radicals and peroxides that can damage the cell.10 The most 
major of the long term effects is the damage of DNA. Metals such as iron are capable of 
catalyzing some redox cycle reactions via electron transfer process.  
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Figure 1.3.  Overview of various oxidative stress-related effects on the cell, that would 
contribute to cell death.25  
 An experiment was designed to identify cellular proteins capable of binding to carnosine 
and heme-chelated carnosine.  A carnosine affinity column was developed by attaching 
carnosine to benzyloxybenzylbromide resins via the peptide’s N-terminus.  In addition, heme-
chelated carnosine affinity beads were created by passing a solution of hemin through the 
carnosine affinity columns.  Tissue samples were lysed and incubated with the affinity beads, 
and mass spectrometry was used to identify all the proteins capable of binding to these affinity 
beads.  By identifying these protein-binding partners, a better understanding can be gained of the 
cellular action of carnosine and heme-chelated carnosine; this could eventually lead to the 
development of novel drugs for the treatment of a variety of diseases.  
Spontaneous glycation of protein amines by sugars is a reaction that can lead to protein 
modification and dysfunction.  The glycation of proteins begins with the formation of an 
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unstable Schiff base that occurs between the carbonyl group of the reducing sugars D-glucose or 
D-galactose and the free amino groups on proteins.  This Schiff base then rearranges to form a 
more stable Amadori product that with time forms a heterogeneous group of compounds referred 
to as Advanced Glycation End Products (AGEs).11-13  A schematic showing the formation of 
glycation products is shown in Figure 1.4.  Protein glycation is influenced by many factors in 
vivo, including the nature and concentration of the carbonyl substrates, the availability and 
reactivity of the amino groups on proteins, and the chemical or enzymatic degradation of 
glycation products and their renal clearance.14-15 
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Figure 1.4.  Glycation 
 Cytochrome c (cyt c), a c-type heme protein containing a heme moity covalently attached to the 
polypeptide chain, plays a role in both cellular respiration and apoptosis.  Cyt c, the only 
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nonintegral protein involved in the electron transport chain, associates with its respiratory partner 
cytochrome oxidase by use of a group of lysines rimming the heme edge allowing heme-to-heme 
contact needed for efficient electron transfer.16  ATP has been proposed to serve as an important 
inhibitory regulator of respiratory activity in the cell by shifting these lysines away from this 
interaction upon binding to cyt c.17   Cyt c is also a key player in the cellular apoptosis process in 
that one of the triggering events of apoptosis is the release of cyt c from the inner mitochondrial 
membrane into the cytosol of the cell.  Additional lysines on the surface of cyt c have been 
shown to be important in the binding of cyt c to the membrane, and the glycation of these 
residues could interfere with its membrane binding properties and have an effect on the apoptosis 
process.  Cyt c has a cluster of lysine residues surrounding the heme edge that are involved in the 
electrostatic interaction with negatively charged lipids.  When bound to anionic lipids, cyt c 
orients the side bearing Lys-72, 86 and 87 towards the membrane surface with the heme 
favorably exposed for the electron transfer activity.18   
 We propose that the glycation of cyt c with D-galactose could alter critical functional lysine 
groups on this protein, leading to impaired functions in respiration and apoptosis.  A student 
working in the Frost lab, Mr. Derrick Collins, has previously identified the preferential sites of 
glycation when cyt c was condensed with D-galactose in vitro.  Table 1 below summarizes the 
data that he obtained and shows the sequences and the location of D-galactose in each of the 
glycated peptides observed.  Mr. Collins also determined the effect of carnosine on the initial 
glycation of cytochrome c with D-galactose by monitoring the mass shifts that occurred when the 
protein was glycated (+162 Da/alactose addition).  Protein samples incubated with D-galactose 
in the presence and absence of carnosine were analyzed daily for eleven days by MALDI-TOF 
mass spectrometry.  The resultant mass spectra can be seen in Figure 1.5.  The glycation pattern 
8 
 
when carnosine is added to the incubation mixture remains similar to when it is absent, 
indicating that carnosine does not inhibit the initial glycation reaction between cyt c and 
galactose.  The glycation could only be monitored for 11 days, because the protein began to 
degrade in the constant presence of carnosine and galactose.  Since carnosine did not inhibit the 
initial attachment of a sugar molecule to the cyt c protein, we propose that carnosine may be 
involved in protection against the formation of the advanced glycation endproducts that occurs 
over time after the sugar is added to the protein.        
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Table 1.1 
Glycated peptides in Cytochrome C identified by MALDI-TOF and LC/ESI/MS/MS 
 
Galactated cytochrome C was prepared by incubating the native protein (1.0 mg) with D-
galactose (35 mg) in 500 µL of PBS, pH 7.4, for 24h at 37°C.      
*Denotes that these sites represent galactated lysine residues. 
♦Denotes that this site represents an oxidized methionine residue. 
(a) The peptide at m/z 1840 was a mixture of two peptides, one with 25K modified and one with 27K modified. 
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Figure 1.5.  MALDI-TOF mass spectra of the +2 ion of bovine Cyt c incubated at 37°C in the 
presence of D-galactose for 2 days (A), 4 days (B), 7 days (C), and 11 days (D).  Bovine 
cytochrome c incubated at 37°C in the presence of D-galactose and carnosine for 2 days (E), 4 
days (F), 7 days (G), and 11 days (H). 
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Experimental Methods:  
Preparation of Carnosine Affinity Beads:   
Carnosine affinity beads were produced by attaching carnosine to 
benzyloxybenzylbromide resins (Advanced ChemTech) through its N-terminus following the 
manufacturer’s protocol. We spent some time optimizing all of the experimental conditions in 
order to produce the best quality affinity beads possible. Briefly, the resin beads were swelled in 
dichloromethane (DCM) for an h and then washed 3X with dimethylformamide (DMF). 17 mg 
carnosine was then dissolved into 200 µL of DMF and added to the resin. This was allowed to 
stir overnight at room temperature. A NP-40 lysis buffer composed of 50 mM Tris-HCl at pH 
8.0, 150 mM NaCl and 1% NP-40 was prepared. The resin was washed three times with DMF, 
three times with DCM and three times with the lysis buffer. The same process was repeated for 
the pre-clear beads without the addition of carnosine.  
Beads were also created with a similar method for connecting via the C-terminus, though 
results of the experiment were inconclusive.   
Later trials involved the preparation of NHS Magnetic carnosine affinity beads through 
covalently binding carnosine to NHS magnetic beads (PureProteome) via its N-terminus 
following the manufacturer’s protocol. Briefly, 200 µg of carnosine was dissolved into 60 µL of 
phosphate buffered saline (PBS). Sixty µL of the 20% bead slurry was removed and added to a 
separate 1.5 mL microcentrifuge tube. This was placed into the magnetic stand and the beads 
were allowed to migrate to the magnet where the storage buffer was removed. Immediately, 500 
µL of ice-cold equilibration buffer was added to the beads. This buffer was a 50/50 solution of 
distilled water and HCl. The beads were then vortexed rigorously and placed back into the stand 
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where the solution was removed. Next, the carnosine solution was added to the beads and the 
tube was removed from the stand. The beads were then incubated with continuous mixing at 
room temperature for 4 h. Afterwards the beads were placed in the magnetic stand and allowed 
to migrate to the magnet before the unbound C-Peptide solution was kept back for analysis. Five 
hundred µL of the Quench Buffer (100 mM Tris-HCl, 150 mM NaCl, pH 8.0) was added and 
vortexed rigorously for 30 s. The beads were placed back into the stand and the solution was 
removed. This process was repeated another four times. A final 500 µL of the Quench buffer is 
added then allowed to incubate with the beads at room temperature with continuous mixing for 1 
h. Afterwards, the beads are placed in the stand, the quench buffer is removed and the beads are 
stored in 100 µL of PBS. The process was repeated for the pre-clear beads without addition of 
carnosine.  
 
Tissue Lysis: 
 For the initial experiments, we isolated proteins from two types of bovine tissues, 
specifically: heart and kidney. There were three trials for this initial experiment. The first two 
used tissue from bovine heart, and the last trial from bovine kidney. Bovine tissue was lysed 
using CelLytic MT mammalian tissue lysis buffer (Sigma) following the manufacturer’s 
protocol.  Protease inhibitors were added to the lysis buffer.  Briefly, the tissue was homogenized 
in lysis buffer and allowed to sit on ice for 30 min to ensure optimal lysis of the tissue. The tissue 
lysate was then centrifuged at 12,000 G for 15 min at 4°C, and the supernatant lysate was 
transferred to a clean microcentrifuge tube.  Uncoupled benzyloxybenzylbromide beads were 
added to the lysate to preclear the lysate of any proteins that would have an affinity for the beads 
themselves.   
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 The later experiments with magnetic beads involved the lysis of bovine kidney, first, then 
later the use of lean Zucker rat plasma.  
Protein Isolation: 
 Proteins capable of binding to carnosine and/or heme-chelated carnosine were isolated 
using the affinity beads created above.  We optimized all experimental conditions (time, 
temperature, etc.) until we were able to isolate proteins from different tissue lysates.  Briefly, 
pre-cleared lysates were incubated with carnosine affinity beads overnight at 4 °C.  After the 
reaction was complete, the supernatant was removed, and the beads were washed 3X with 
phosphate buffered saline (PBS).   
SDS PAGE Analysis of Isolated Proteins:  
Proteins isolated from the affinity columns were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) prior to mass spectrometric analysis.  
Proteins were eluted from the affinity beads with the addition of SDS-PAGE sample loading 
buffer and loaded directly onto the PAGE TGXTM gels (4-15% gels, BioRad).  Briefly, proteins 
were separated for 30 min at 200V using Tris/Glycine/SDS running buffer. DTT (0.1 M) was 
added directly to the samples, and all samples were heated for 5 min at 100°C prior to gel 
loading.  Proteins were visualized with Bio-Safe Coomassie Stain (Bio-Rad). 
Preparation of Tryptic Digests of Protein Samples from SDS-PAGE Bands: 
 Protein bands were excised, reduced with DTT, treated with iodoacetamide, and digested 
with trypsin overnight at room temperature following the procedure at http://ms-
facility.ucsf.edu/ingel.html.   
Briefly, protein bands were excised from gel, diced into smaller pieces and placed in .5 
mL siliconized  tubes. 100 µL of 25 mM NH4HCO3/50% ACN was added to the gel pieces and 
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vortexed for 10 min. A gel loading tip was used to extract the supernatant that was discarded. 
This was repeated twice more until the gel pieces no longer contained visible staining. Next, a 
fresh solution of 10 mM DTT in 25 mM NH4HCO3 was prepared. About 25 µL of DTT was 
added to each tube. They were vortexed and spun briefly before being allowed to incubate at 56º 
C for 1 h. Then the supernatant was removed and discarded and 30 µL of a freshly prepared 55 
mM iodoacteamide in  25 mM NH4HCO3 was added to the gel pieces. These were allowed to 
incubate in the dark for 45 min. The supernatant was then removed, and 100 µL of NH4 HCO3 
was added to wash the gels and was then removed. Next, the gels were washed twice with 100 
µL of 25 mM NH4HCO3/50% acetonitrile (ACN) . All supernatant was removed. Then, a 
solution containing 0.2 µg trypsin in 30 µL of 25 mM NH4HCO3 was added to each gel piece and 
allowed to digest over night. The digest solution was transferred into a clean siliconized tube, 
and to the gel pieces, 30 µL of 50% ACN/5% formic acid was added, and vortexed for 30 min. 
These were then spun down and sonicated. The solution was removed and  the digest solution 
was added. The process was then repeated once more. The resulting digest solution was then 
placed into a centrifugal evaporator where the solutions were reduced to a volume of 10 µL. 
 
Analysis of Tryptic Digests of Proteins by MALDI-TOF Mass Spectrometry: 
 The tryptic digests of the proteins were purified with C18 ZipTips (Millipore) and 
analyzed on a Bruker Autoflex  MALDI-TOF mass spectrometer (Billerica, MA).  Prior to 
analysis, the peptide preparations (0.6 µL) were each mixed with a 50% aqueous acetonitrile 
solution (0.6 µl) of saturated α-cyano-4-hydroxy-cinnamic acid containing 0.05% TFA as matrix, 
spotted onto a stainless steel sample plate and allowed to air dry.  The mass spectra were 
recorded in positive ion mode with a 60 nsec delay in the m/z range from 500 to 3500.  
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Typically, 500 spectra will be accumulated with 50 laser shots for each sample spot analyzed.  
The resulting peptide mass fingerprint spectra obtained for each protein analyzed was used to 
identify the protein by inputting the peptide molecular weights obtained into the mascot search 
engine.19  
Analysis of Tryptic Peptide Amino Acid Sequences by LC/ESI/MS:  
The tryptic digests of the proteins were purified with C18 ZipTips (Millipore) and 
analyzed on a ThermoFinnigan LCQ mass spectrometer.  The tryptic peptides were fractionated 
on 10µm spherical C18  resins and eluted directly into the electrospray source of a 
ThermoFinnigan LCQ mass spectrometer equipped with a quadrupole ion trap mass analyzer.    
The reverse phase microcapillary columns were constructed according to a procedure modified 
from Kennedy and Jorgensen.20   The loading of peptides onto the columns was performed using 
a helium bomb.  Once applied to the columns, the peptides were first washed with 0.1% acetic 
acid for 3 min and were then collectively eluted from the columns with 60% acetonitrile in 0.1% 
acetic acid at a flow rate of 2 µL/min using the helium bomb.  The column elutes directed into 
the electrospray source were analyzed by MS and tandem mass spectrometry (CID fragmentation 
with He) favoring isolation and fragmentation of doubly charged ions. 
The ESI/MS system was operated with the Xcalibur software (version 2.0, 
ThermoFinnigan), with the same software used also for data analysis.  The mass spectrometer 
was set to function in the positive ion mode with parameters optimized during direct infusion of 
peptide standards with solvent. The solvent, consisting of 50/50 (v/v) 0.1% acetic acid in 
water/acetonitrile, was applied at a flow rate of 3 µL/min.  Nitrogen was used as the sheath gas 
(setting at 60), and ultrapure helium was used as the collision gas.  The ion spray voltage was set 
as 4.5 kV and the capillary temperature was 210°C. 
Determining the Effect of Carnosine on AGE Structure Formation:  
Glycated cytochrome C was prepared by incubating 1 mg of bovine cyt c with 35 mg of 
D-galactose in 250 µL of PBS, pH 7.4 at 550C for 3 h.  After incubation, an Ultracel YM-33 kDa 
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cutoff filter was used to remove excess galactose from the sample prior to further analysis.  The 
sample was diluted to a volume of 250 µL with PBS and 125 µL of sample was transferred to a 
new microcentrifuge tube.  Carnosine was added to one sample at a final concentration of 10 
mM, and both samples were diluted to 500 µL with PBS and allowed to incubate at 370C for up 
to 42 days. 
Sodium Borohydride Reduction:   
A freshly prepared 100 mM solution of sodium borohydride in 0.02N NaOH was 
immediately reacted 1:1 with each of the cytochrome c protein preparations.  Incubations were 
allowed to proceed at room temperature for 1h, and reactions were terminated by 1N HCl (1:12.5 
vol/vol). Following the addition of HCl to samples, mixtures were incubated at room temperature 
for 5 min. The pH of samples was then adjusted to physiological pH by a 1:1 dilution with a 100 
mM Tris buffer, pH 7.5. 
 
UV-VIS absorbance profile of hemin:  
Hemin was added to a saturated solution of carnosine in PBS at pH 7.4. After 30 min, 
absorbance spectra were measured on a Cary 50 Scan UV-Visible spectrophotometer. 
 
 
 
 
Results and Discussion: 
Identification of Carnosine Binding Proteins Isolated from Bovine Kidney Tissue: 
17 
 
Carnosine is a rather simple dipeptide that could act as a signal or cofactor for cellular 
processes in the body. Little is known as of yet about the biological function of this dipeptide. 
Knowledge gained from previous studies in the Frost lab showed that carnosine acts on heme 
possibly via chelation of the iron atom in the heme to the His residue of carnosine. This 
experiment was designed to gain a better understanding of how carnosine acts in the body by 
examining what proteins an affinity column with carnosine attached would pull out of cell 
lysates. By knowing the proteins, inferences can be made as to how carnosine works with these 
known proteins in the body. 
The basic protocol for this experiment is summarized in Figure 1.6.  We developed 
carnosine affinity beads by attaching carnosine to benzyloxybenzylbromide resins via the 
peptide’s N-terminus.   We then lysed bovine kidney tissue and incubated the cellular lysates 
with the affinity beads overnight at 4 °C (lysates were pre-cleared with uncoupled 
benzyloxybenzylbromide resin beads).   Proteins isolated with the affinity beads were separated 
by reducing SDS-PAGE, digested with trypsin, and analyzed by MALDI-TOF mass 
spectrometry.  The SDS-PAGE gel is shown in Figure 1.6.  Lane 1 of the gel contained 
molecular weight markers from which we could obtain approximate molecular weight values for 
the proteins isolated from the beads.  Lane 2 contained bovine kidney lysate. This lane is the 
darkest because it contains all of the proteins extractable in the lysate. Lane 3 was left blank, and 
lane 4 contained proteins isolated from bovine kidney tissue lysates. Several Protein bands 
appeared, but three at approximately 150 kDa, 60 kDa, and 37 kDa (labeled in figure 1.7) were 
further analyzed by mass spectrometry.   
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Figure 1.6.  Basic experimental protocol for protein isolation using the carnosine affinity beads. 
 
Figure 1.7.  SDS-PAGE gel separation of proteins.  Lanes: 1) molecular weight markers, 
2) kidney cell lysate, 3) “blank”, 4) proteins eluted from kidney cell lysate using carnosine beads. 
Protein bands 1, 2, and 3 were excised from the gel for further analysis.  
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The proteins in bands 1, 2, and 3 from the SDS-PAGE gel were identified by mass 
spectrometry through the technique of Peptide Mass Fingerprinting (PMF). In PMF, an unknown 
protein is cleaved into smaller peptide fragments using a specific protease, most commonly 
trypsin.  The molecular weight of each fragment peptide is then accurately measured by mass 
spectrometry. These peptide masses are then compared to a computer database of known protein 
sequences. Mascot, a computer program, works to take the unknown sequence from the database 
and compares them with the masses in order to determine a protein match. In this experiment, the 
proteins isolated were identified via excising a protein band from the gel, digesting the protein 
with trypsin, and analyzing the resulting peptide fragments with MALDI-TOF mass 
spectrometry. 
 We were able to successfully identify several putative carnosine-binding proteins from 
bovine kidney tissue using our carnosine affinity beads (Table1. 2).   The MALDI-TOF mass 
spectrum generated from the tryptic digest of the protein at about 37 kDa in lane 4 of the SDS-
PAGE gel (marked as 1 in figure 1.7) is shown in Figure 1.8.  This protein was identified as 
haptoglobin.  Haptoglobin (Hp) is a protein involved in the removal of free hemoglobin from 
plasma (Figure 1.9).  Hp is an acute phase protein whose transcription is increased in response to 
inflammatory stimuli.  Hp functions to bind to free hemoglobin in the plasma. From here, the 
hemoglobin can be degraded by enzymes instead of going to the kidney, preventing iron loss and 
kidney damage by the hemoglobin.21 The protein is produced primarily in hepatocytes, as well as 
in other tissues such as epithelial, lung and kidney tissues. Carnosine could be chelating to the 
heme group of hemoglobin and assisting in the heme detoxification process.  
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Table 1. 2.  Carnosine-binding proteins identified by mass spectrometry. 
 
 
Figure 1.8.  MALDI-TOF peptide fingerprint mass spectrum for the protein excised from 
band 1 of the SDS-PAGE gel (Figure 5). 
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Figure 1.9.  Binding of haptoglobin to hemoglobin and uptake of the complex by the 
CD163 receptor expressed on macrophages.22 
The MALDI-TOF mass spectrum generated from the tryptic digest of the protein at about 
60 kDa in lane 4 of the SDS-PAGE gel (marked as 2 in figure 1.7) is shown in Figure 1.10.  This 
protein was identified as the alpha subunit of T-complex protein 1 (TCP-1).  This mass spectrum 
also contained peptide peaks from actin.  TCP-1 is a 1-MDa oligomer that is built by two rings 
comprising eight different 60-kDa subunits that functions to push polypeptides through it using 
the energy of ATP hydrolysis to fold the proteins (Figure 1.11).23  TCP-1 is a chaperonin that 
regulates the folding of important proteins including actin, α-tubulin and β-tubulin. Proteins may 
misfold or unfold in the face of certain stresses, such as changes in the cellular environment due 
to ageing, temperature fluctuations, or reactive oxygen species.  Chaperonins act as essential 
modulators of protein homeostasis to minimize aberrantly folded species by promoting their 
productive folding or degradation.  Carnosine could be chelating to the heme group in partially 
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unfolded heme proteins and delivering them to the TCP-1 complex for refolding through its 
interaction with the alpha subunit.   
 
 
Figure 1.10. MALDI-TOF peptide fingerprint mass spectrum for the protein excised 
from band 2 of the SDS-PAGE gel (Figure 5). 
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Figure 1.11.  TCP-1 chaperonin with its eight different subunits, depicted in green.12  The red T 
represents ATP, and the grey D represents ADP. 
 
 The MALDI-TOF mass spectrum generated from the tryptic digest of the protein at about 
150 kDa in lane 4 of the SDS-PAGE gel (marked as 3 in figure 1.7) is shown in Figure 1.12.  
This protein was identified as actin.  The protein molecular weight of 150 kDa does not correlate 
with the known molecular weight of actin of 45 kDa.  Either the protein in this band is a 
polymerized trimer of the protein, or the MALDI-TOF plate contained trace amounts of a 
previous actin digest at this spot on the plate.    
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Figure 1.12.  .MALDI-TOF peptide fingerprint mass spectrum for the protein excised 
from band 3 of the SDS-PAGE gel (Figure 1.5). 
 
Identification of Carnosine Binding Proteins Isolated from Mouse Kidney Tissue: 
We repeated this experiment using a different type of beads and using a tissue lysate 
obtained from bovine kidney tissues and later rat plasma.  We developed affinity beads by 
attaching carnosine to NHS magnetic beads via the peptide’s N-terminus.   
The NHS carnosine affinity beads identified haptoglobin again in both the plasma and the 
tissue, but none of the other proteins found in the bromophenoxy resin trials were identified. 
There were bands in the gel that could have corresponded to these proteins, but they could not be 
identified.  
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Additionally, the beta subunit of hemoglobin (HBB) was found multiple times in both the 
bovine kidney tissue and in the rat blood plasma. The peptide mass fingerprint spectrum from 
one of the Bovine Kidney trials can be found in figure 1.13. This finding is particularly 
interesting because it ties in with the binding of carnosine with the iron in the heme. HBB has a 
molecular weight of about 15.9 kDa. Its structure can be seen in Figure 1.14. HBB is involved in 
oxygen transport and is only found in red blood cells. It is a globular protein that forms a 
heterotetramer, along with a second HBB and two alpha hemoglobin subunits (figure 1.15)26. 
Carnosine’s ability to bind with HBB helps to confirm the possible interactions of carnosine with 
heme-containing proteins. Postulations could be that carnosine can bind to HBB so that it can 
more easily bind to the iron atom in the heme when necessary. Carnosine’s ability to bind to 
HBB could also directly tie in with haptoglobin’s binding to hemoglobin. Perhaps the common 
binding partner assists both. 
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Figure 1.13. The Peptide Mass Fingerprint spectra for a bovine kidney trial using the Magnetic 
beads. Excised from approximately 20 kDa.  
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Figure 1.14. The structure of HBB based on PyMOL rendering of PDB.  
 
Figure 1.15. The structure of the hemoglobin heterotetramer including the four heme groups. 
Red represents the alpha subunit and blue represents the beta subunit. Based on a PyMol 
rendering of PDB. 
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Effect of Carnosine on the Formation of AGEs: 
In order to study the effect of carnosine on the formation of AGEs, we initially incubated 
cyt c with galactose for 3 h at 55°C.  The sugar was then removed, and the remaining protein 
solution was split into two equal portions.   Carnosine was added to one sample to a final 
concentration of 10 mM, and both samples were diluted to equal volumes with buffer.  The 
samples were then incubated at 37°C for 42 days.  Aliquots of protein were removed periodically 
and analyzed by MALDI-TOF mass spectrometry.  The resultant mass spectra for the protein 
samples after 42 days of incubation can be seen in Figure 1.16.  The glycated cytochrome c that 
was not incubated with carnosine (Figure 1.16A) has a more prominent peak in the spectra at 
about m/z 6140 (indicated by the arrow) than when the protein was incubated in the presence of 
carnosine.  This peak had a mass that was about 58 Da greater than the mass of the unmodified 
protein that would indicate the formation of an AGE structure.  These results suggest that 
carnosine can slow down or inhibit the formation of AGE structures that can form after the initial 
glycation of the protein.   
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Figure 1.16.  MALDI-TOF mass spectra of the +2 ion of glycated cytochrome c 
incubated at 370C in the absence of carnosine (A) and in the presence of carnosine (B) for 42 
days.   
 To investigate this further, the glycated proteins incubated with and without carnosine for 
42 days were reduced with NaBH4 and separately reacted with trypsin.  The tryptic digest from 
each was analyzed by MALDI-TOF mass spectrometry in order to determine the glycation sites.  
The resultant peptide mass fingerprint spectra can be seen in Figure 1.17.  The mass region 
between 2230 Da and 2430 Da was expanded and is displayed in Figure 1.18. 
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Figure 1.17.  MALDI-TOF tryptic peptide mass fingerprint spectra of cytochrome C incubated 
at 55°C for 3 h in the absence of sugar (A), and glycated cytochrome C incubated at 37°C for 42 
days in the absence of carnosine (B) and in the presence of carnosine (C).  All protein samples 
were reduced with sodium borohydride prior to tryptic digestion. 
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Figure 1.18.   MALDI-TOF tryptic peptide mass fingerprint spectra of cytochrome C 
incubated at 550C for 3 h in the absence of sugar (A), and glycated cytochrome C incubated at 
370C for 42 days in the absence of carnosine (B) and in the presence of carnosine (C).  All 
protein samples were reduced with sodium borohydride prior to tryptic digestion.  
The amino acids Lys-13, 25, 72, and 88 have previously been identified as preferred 
glycation sites when cyt c was incubated with D-galactose. The presence of 10 mM carnosine 
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was shown to inhibit the formation of AGE structures on glycated cytochrome c (Figure 1.16).  
In particular, glycated Lys-13 (∆164 amu when reduced with NaBH4) was not converted to the 
AGE structure (∆ 58 amu) when carnosine was added to the incubation mixture (Figure 1.18).  
The identification of the modified lysine groups was confirmed by CAD mass spectra of the 
peptides at m/z 2307 and 2413. Lys-13 is located right next to the heme group in cytochrome c 
(Figure 1.19).  We propose that the heme group facilitates the conversion of the glycated lysine 
residue into the AGE structure.  The carnosine may be associating with the heme group keeping 
it in its reduced form (Fe+2).    
 
Figure 1.19. Space-filling plot of the horse cytochrome c structure.  Modified lysine 
residue is shown in yellow and heme group is shown in grey.  Adapted from the high-resolution 
3-D structure of horse cytochrome c24 available at the Protein Data Bank PDB ID:1HRC. 
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Analysis of Carnosine-Hemin Interactions: 
The results from the previous experiments indicate that carnosine interacts with heme 
groups.  Carnosine contains a histidine group as part of its structure, and histidines are known to 
ligate to the Fe ion in heme groups.  In fact, heme is attached to the proteins hemoglobin and 
myoglobin through a ligand interaction between the Fe atom and a proximal histidine residue 
located in the heme-binding site.  Hemin is protoporphyrin IX (heme B) containing a ferric iron 
ion (Fe+3).  We have found that the addition of carnosine to a solution of free hemin drastically 
increases the solubility of hemin and causes a shift of the λmax in its UV-Vis absorbance profile.  
The wavelength of the Soret band maxima of hemin in PBS at pH 7.4 is 386 nm.  When 
carnosine was added to the solution, the wavelength maxima shifted to 408 nm (Figure 1.20).  In 
addition, the bands arising from the Q bands were shifted.  This significant change in the heme 
active site in the presence of carnosine may correspond to a 6c low-spin Fe+2 state for the heme.  
These results suggest that the carnosine was ligating to the iron most likely through the histidine 
side chain.  The conversion of the oxidized iron in hemin (Fe+3) to the reduced (Fe+2) state would 
be beneficial to cells because the Iron II state cannot catalyze the production of free radicals in 
the cell therefore preventing oxidative stress. 27   
 
34 
 
Figure 1.20. UV-VIS absorption profile of hemin in a saturated solution of carnosine.  
Inset is the absorption profile of hemin in PBS. The dimer absorbs at 345 nm, while the 
monomer absorbs at 386 nm. 
Future Work 
Further research could delve into the possibilities of using carnosine as a drug to prevent 
heme toxicity in the body. Carnosinase will degrade free carnosine in the blood stream meaning 
increasing the amount of carnosine in the body would likely increase degradation. To avoid this, 
carnosine could be derivatized so that carnosinase will not recognize it as a substrate. However, 
without a complete understanding of the biological function of carnosine, it would be difficult to 
predict how the derivatization would affect its function.  In addition, this would have to be 
carefully regulated, because too much carnosine could cause carnosinemia in patients. Excess 
amounts of carnosine have been known to harm people causing various forms of neurological 
problems.  
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Because the tissue and plasma utilized in these experiments had been frozen a few years, 
it is possible the time could have degraded some of the protein’s binding abilities. Future 
experiments could involve repeats of the affinity column experiment with fresher tissue samples. 
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Proinsulin C-Peptide as an Active Biomolecule 
Introduction: 
Proinsulin connecting peptide, or C-peptide, is part of a precursor to insulin in the insulin 
biosynthesis pathway. 1 The 31 amino-acid peptide (Figure 2.1) serves to connect the A chain to 
the B chain in proinsulin and facilitates the correct folding of proinsulin to allow the formation of 
the disulfide bridges between the A-chain and the B-chain of insulin. 
 
Figure 2.1. Structure of insulin C-peptide. 
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Figure 2.2. Proinsulin structure.  The mature insulin peptide is shown in red and the C-peptide is 
shown in yellow. 
 
Proinsulin (Figure 2.2) is formed within pancreatic β-cells. In the insulin biosynthesis 
pathway (figure 2.3), C-peptide is cleaved off via a trypsin-like protease located in the 
endoplasmic reticulum of pancreatic β-cells. C-peptide is then stored in Golgi secretory 
granuoles along with mature insulin peptide and is secreted in equimolar amounts along with 
insulin into the portal circulation. Although C-peptide has long been considered biologically 
inert, there is some evidence that it has a function within the body. C-peptide is stored in 
pancreatic β-cells along with insulin and released into circulation with insulin. It is used as a 
marker for distinguishing Type-1 diabetes from Type-2.  C-peptide also has a considerably 
longer half-life in the body than insulin.  C-peptide is cleared by the kidney and has a half-life of 
about 20 to 30 min compared to insulin that is cleared through the liver and has a half-life of 
about 3 to 5 min.2 
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Figure 2.3. Insulin Biosynthesis Pathway as proposed in “Insulin Biosynthesis: Evidence for a 
Precursor”.1  
C-Peptide levels are closely tied with insulin since they are created in a one to one ratio. 
C-Peptide can be used as a marker of insulin production and is used to help determine the 
difference between a person with Type-1 diabetes and Type-2. In Type-2, more insulin and C-
peptide are synthesized as where in Type-1, considerably less insulin and c-peptide is produced. 
The primary difference in the diabetes types is Type-2 is associated with insulin resistance and 
initially has normal or elevated levels of insulin and c-peptide that can decrease over the course 
of the disease, and Type-1 is associated with less insulin production due to a decrease in 
functional pancreatic β-cells.3 Diabetes is a group of metabolic diseases associated with high 
blood glucose levels. Insulin is the primary peptide hormone associated with diabetes. It works to 
inhibit glucagon release and thus regulate carbohydrate and fat metabolism. Insulin binds to 
receptors on cells found in the liver, skeletal muscles, and fat causing glucose absorption. Insulin 
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is medically used to treat patients with diabetes; however, insulin treatment has been shown to 
lower C-peptide levels in Type-2 diabetics.4 
 
Type-1 diabetes is associated with a lowered production of insulin and a loss of insulin-
producing pancreatic beta cells.3 Approximately 10% of diabetics have this type. It involves 
sudden onset before age 40 and is considered insulin-dependent. Type-2 diabetes, on the other 
hand, is characterized by low insulin-sensitivity and high insulin production. Approximately 
90% of diabetics have this type and it primarily affects obese adults with gradual onset. 
Symptoms of diabetes are numerous involving both microvascular and macrovascular 
complications. Microvascular issues include retinopathy (cataracts, and glaucoma in the eyes), 
nephropathy (microalbuminuria and kidney failure), and neuropathy (nerve damage in the 
peripheral nervous system). Macrovascular complications include stroke, cognitive impairment, 
coronary syndrome, myocardial infarction, congestive heart failure, peripheral vascular disease 
leading to gangrene, ulceration and amputation. Typically microvascular complications are more 
associated with Type-1 and macrovascular complications more with Type-2; however, some 
complications are shared.  
Because C-peptide is synthesized in a one to one ration with insulin, it has been 
suggested that it may also have a function in preventing diabetes. For this reason, and for the fact 
that C-peptide is not degraded immediately after the correct folding and processing of the mature 
insulin peptide, C-peptide has been the subject of several major studies that show a more active 
role in the body. C-peptide is now believed to be an important, biologically active molecule that 
can improve some of the complications associated with diabetes mellitus.  The biological 
functions of C-peptide are still being heavily investigated, but the peptide is thought to exert its 
biological effects through both receptor-mediated and non-receptor mediated pathways.  
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Studies have been conducted that demonstrated beneficial effects of the C-peptide in the 
diabetic state, including improvements of kidney and nerve function.  C-peptide has been shown 
to bind to membrane surfaces of cultured cells derived from human renal tubules, skin 
fibroblasts, and saphenous vein endothelium.2,5-7  The pretreatment of cells with pertussis toxin, 
known to modify receptor-coupled G proteins, abolished the binding, so it was concluded that 
the C-peptide was binding to specific G protein-coupled receptors on cell membranes. 7 
However, a C-peptide specific cell surface receptor has never been isolated or identified to date.    
C-peptide has also been shown to stimulate Na+K+-ATPase and endothelial nitric oxide synthase 
activites.5 These results have led Wahren, et al.5 to propose the mechanism of action of C-peptide 
shown in Figure 2.4 below.      
 
 
Figure 2.4.  Proposed mechanism for C-peptide signaling cascade.5 
 
 
Some studies have been conducted on the influence of C-Peptide on Atherosclerosis. 
Atherosclerosis is a common occurrence in diabetic patients. It is defined as the buildup of 
plaque in arteries that causes blockage and several cardiovascular disorders.  C-Peptide has been 
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shown to induce an increase in Nitric Oxide in aortic cells to act as a pro-atherogenic effect. 8 
Interestingly, the dilation could not be replicated in other tissues. In endothelial cells, on the 
other hand, C-Peptide was shown to induce arteriolar dilation via nitric oxide dependent 
mechanisms. An overabundance of C-Peptide would cause inflammation, but a healthy amount 
causes dilation. (Figure 2.5) 
 
Figure 2.5.  Depiction of the role of C-peptide in atherosclerosis.8 
  
There have been several human studies conducted on people suffering from Type-1 
diabetes. Low C-peptide levels in Type-1 patients is negatively correlated with microvascular 
44 
 
complications including retinopathy, neuropathy and nephropathy when compared to Type-2 
patients.9 C-Peptide infusion in these patients leads to a nitric oxide mediated increase in arm 
blood flow while greatly reducing microalbuminuria and glomerular filtration rates.10,11 C-
Peptide also helps to improve nerve conduction velocity and lessen autonomic dysfunction. 12 
 Type-2 diabetics in early stages typically have considerably more C-Peptide than a non-
diabetic and many negative complications of the disease can be correlated with the high C-
Peptide levels. There is a positive correlation of fasting C-Peptide levels with cardiovascular 
death and mortality.13 Increased C-Peptide serum levels correlate with several risk factors for 
coronary artery disease including systolic blood pressure and dyslipidemia. There is a positive 
association with macrovascular complications in Diabetes Type-2 patients and C-Peptide 
levels.14 C-Peptide levels have a significant correlation with all-cause and cardiovascular deaths. 
15
 Endothelial dysfunction and atherosclerosis can be found in Type-2 patients with high C-
peptide levels. 16 
  C-peptide was found to disrupt insulin aggregation in vitro as well as influence insulin to 
insulin interactions.17  These findings could be an explanation for why C-peptide is stored with 
insulin in the pancreas.  
 Lindahl et al. conducted an experiment similar to ours in premise.18 Biotinylated C-
Peptide immobilized to an SA-chip has lysate run over it at 10 µL/minute using 0.4% 
deoxycholate as the lysis detergent and employing human embryonic kidney (HEK-293) cell 
cultures as the tissue type. Any proteins found to bind with the C-Peptide were digested with 
trypsin, and analyzed with a MALDI-MS. A Peptide Mass Fingerprint was used to identify the 
proteins that could bind. They identified calcium-dependent serine protein kinase (CASK), as 
well as some cytoskeletal and cytoskeletal-associated proteins. CASK is a peripheral plasma 
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membrane protein, and a multi-domain scaffolding protein. It has a role in transmembrane 
protein anchoring and Ion channel control. Unlike most kinases, CASK does not require a 
divalent cation cofactor to operate catalytically. It binds to many cell-surface proteins found in 
the membrane.  The authors believed most of their findings to be considered “sticky” proteins 
and did not offer a suggestion as to the reasoning for the binding capabilities to C-Peptide. We 
would like to improve upon their experiment in a couple of ways. Biotinylation takes advantage 
of the natural affinity of biotin for avidin. Avidin is a 66 kDa protein, and interactions between it 
and C-Peptide could easily be occurring. We proposed to use a different kind of affinity column 
that does not rely on protein interactions. Their detergent choice, deoxycholate, is typically 
considered a membrane detergent. Some of the cytosol proteins could have been  lost and/or 
unfolded in the process. We proposed to use the more gentle NP-40 detergent. Their use of 
transformed HEK-293 cells is not optimal either because they are experimentally transformed 
and not a good model for the normal cell. For our experiment, we utilized animal tissue lysates. 
 This experiment was designed to identify cellular proteins capable of binding to C-
peptide. A C-peptide affinity column was developed by attaching C-peptide to NHS magnetic 
beads by the N-terminus. Mouse heart, kidney and liver tissue samples were lysed and incubated 
with the affinity beads, before mass spectrometry was utilized to identify all the proteins capable 
of binding to these affinity magnetic beads. By identifying binding-partners, a better 
understanding can be gained about the cellular processes involving C-Peptide and could help to 
unlock the answers as to why the peptide is not degraded after its purpose of folding is complete. 
Upon the understanding of its purpose in the body, novel treatments could be developed to help 
diabetes patients, especially those suffering from Type-1.  
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Experimental Methods: 
Preparation of C-Peptide Affinity Beads:  
C-Peptide affinity beads were produced by covalently binding C-peptide to NHS 
PureProteome magnetic beads (Millipore) via primary amines (N-terminus and lysine residues) 
following the manufacturer’s protocol. Briefly, 200 µg of human C-peptide was dissolved into 
60 µL of phosphate buffered saline (PBS). To this solution, 30 µL of dimethylformamide (DMF) 
was added. Sixty µL of the 20% bead slurry was removed and added to a separate 1.5 mL 
microcentrifuge tube. This tube was placed into the magnetic stand, and the beads were allowed 
to migrate to the magnet facilitating removal of the buffer solution.  Immediately, 500 µL of ice-
cold equilibration solution (50/50 solution of distilled water and 1 M HCl) was added to the 
beads. The beads were then vortexed rigorously and placed back into the stand, and the solution 
was removed. Next, the C-peptide solution was added to the beads and the tube was removed 
from the stand. The beads were then incubated with continuous mixing at room temperature for 4 
h. Afterwards, the beads were placed in the magnetic stand and allowed to migrate to the magnet 
before the unbound C-peptide solution was removed.  The C-peptide solution removed was used 
to analyze bead binding efficiency.  The magnetic beads attached to C-peptide were then 
vortexed rigorously for 30 s in 500 µL of Quench Buffer (100 mM Tris-HCl, 150 mM NaCl, pH 
8.0).  After mixing, the beads were placed back into the stand, and the solution was removed. 
This process was repeated another four times. A final 500 µL of the Quench Buffer was added 
and allowed to incubate with the beads at room temperature with continuous mixing for 1 h. The 
Quench Buffer was removed, and the beads were stored in 100 µL of PBS. The same procedure 
was followed for the creation of the pre-clear beads either with no peptide attached (skipping the 
incubation with C-peptide step) or substituting the C-peptide with the bradykinin peptide.    
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Tissue Lysis: 
 For these experiments, we isolated proteins from three types of mouse tissues, 
specifically: heart, kidney and liver. Mouse tissue was lysed using a NP 40 lysis buffer (50 mM 
Tris-HCl, 150 mM NaCl, 1% NP 40, pH 8.0) and manual grinding with mini grinders (Bio-Rad 
Ready Prep Mini Grinders).  Protease inhibitors were added to the lysis buffer.  Briefly, the 
tissue was homogenized in lysis buffer and allowed to sit on ice for 30 min to ensure optimal 
lysis of the tissue. The tissue lysate was then centrifuged at 12,000 G for 30 min at 4°C, and the 
supernatant lysate was transferred to a clean microcentrifuge tube.  Pre-clear beads were added 
to the lysate to remove any proteins that had an affinity for beads themselves prior to incubation 
of the lysate with C-peptide beads.   
Protein Isolation: 
 Proteins capable of binding to C-peptide were isolated using the affinity beads created 
above.  We optimized all experimental conditions (time, temperature, etc.) until we were able to 
isolate proteins from different tissue lysates.  Briefly, pre-cleared tissue lysates were incubated 
with C-peptide affinity beads for 4 h at room temperature or overnight at 4°C.  After the reaction 
was complete, the beads were allowed to migrate to a magnet, the supernatant was removed, and 
the beads were washed once with phosphate buffered saline containing tween detergent (PBST) 
and twice with phosphate buffered saline (PBS).  Then, 25 µL of SDS-Page loading buffer 
containing DTT was added to the beads, and the solution was heated for 5 min at 95°C to elute 
any captured proteins from the beads.  The solution containing the eluted proteins was removed 
and placed into a clean microcentrifuge tube.  The C-peptide beads were washed with PBST and 
PBS and stored in PBS at 4°C between uses.   
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SDS PAGE Analysis of Isolated Proteins:  
Proteins isolated from the affinity columns were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis  (SDS-PAGE) prior to mass spectrometric analysis.  Proteins 
were eluted from the affinity beads with the addition of SDS-PAGE sample loading buffer and 
loaded directly onto the PAGE TGXTM gels (4-15% gels, BioRad).  Briefly, proteins were 
separated for 30 min at 200V using Tris/Glycine/SDS running buffer. DTT (0.1 M) was added 
directly to the samples, and all samples were heated for 5 min at 100°C prior to gel loading.  
Proteins were visualized with Bio-Safe Coomassie Stain (Bio-Rad). 
Preparation of Tryptic Digests of Protein Samples from SDS-PAGE Bands: 
 Protein bands from the SDS-PAGE gels were excised, reduced with DTT, treated with 
iodoacetamide, and digested with trypsin overnight at room temperature following the procedure 
at http://ms-facility.ucsf.edu/ingel.html.   
 Briefly, protein bands were excised from gel, diced into smaller pieces and placed in 0.5 
mL siliconized microcentrifuge tubes. 100 µL of 25 mM NH4HCO3/50% ACN was added to the 
gel pieces and vortexed for 10 min. A gel loading tip was used to extract the supernatant that was 
discarded. This was repeated twice more until the gel pieces no longer contained visible staining. 
Next, a fresh solution of 10 mM DTT in 25 mM NH4HCO3 was prepared. About 25 µL of DTT 
was added to each tube. They were vortexed and spun briefly before being allowed to incubate at 
56º C for 1 h. The supernatant was then removed and discarded, and 30 µL of a freshly prepared 
55 mM iodoacetamide in 25 mM NH4HCO3 was added to the gel pieces. These were allowed to 
incubate in the dark for 45 min. The supernatant was then removed, and 100 µL of NH4 HCO3 
was added to wash the gels and was then removed. Next, the gels were washed twice with 100 
µL of 25 mM NH4HCO3/50% ACN. All supernatants were removed. Then, a solution containing 
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0.2 µg trypsin in 30 µL of 25 mM NH4HCO3 was added to each gel piece and allowed to digest 
overnight at room temperature. The digest solution was transferred into a clean tube, and to the 
gel pieces, 30 µL of 50% ACN/5% formic acid was added, and vortexed for 30 min. These were 
then spun down and sonicated. The solution was removed and added to the digest solution in the 
clean tube. The process was then repeated once more. The resulting digest solution was then 
lyophilized (Savant SpeedVac) to a volume of about 10 µL. 
Analysis of Tryptic Digests of Proteins by MALDI-TOF Mass Spectrometry: 
 The tryptic digests of the proteins were purified with C18 ZipTips (Millipore) and 
analyzed on a Bruker Autoflex MALDI-TOF mass spectrometer (Billerica, MA).  Prior to 
analysis, the peptide preparations (0.6 µL) were each mixed with a 50% aqueous acetonitrile 
solution (0.6 µl) of saturated α-cyano-4-hydroxy-cinnamic acid containing 0.05% TFA as matrix, 
spotted onto a stainless steel sample plate and allowed to air dry.  The mass spectra were 
recorded in positive ion mode with a 60 nsec delay in the m/z range from 500 to 3500.  
Typically, ~1000 spectra were accumulated with 50 laser shots for each sample spot analyzed.  
The resulting peptide mass fingerprint spectra obtained for each protein analyzed was used to 
identify the protein by inputting the peptide molecular weights obtained into the mascot search 
engine (Matrix Science Ltd. (2008) MASCOT peptide mass fingerprint. 
http://www.matrixscience.com/cgi/search_form.pl?FORMVER=2&SEARCH=PMF). 
Analysis of Tryptic Digests of Proteins by LC/ESI/MS: 
The tryptic digest of the proteins were fractionated on 10µm spherical C18  resins (YMC, 
Inc. Milford, MA) 
 
and were eluted directly into the electrospray source of a ThermoFinnigan 
LCQ mass spectrometer (ThermoScientific, Waltham, MA) equipped with a quadrupole ion trap 
mass analyzer.    The reverse phase microcapillary columns were constructed according to a 
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procedure modified from Kennedy and Jorgensen.19   The loading of peptides onto the columns 
was performed using a helium bomb.  Once applied to the columns, the peptides were first 
washed with 0.1% acetic acid for 3 min and were then collectively eluted from the columns with 
60% acetonitrile in 0.1% acetic acid at a flow rate of 2 µL/min using the helium bomb.  The 
column elutes directed into the electrospray source were analyzed by MS and tandem mass 
spectrometry (CID fragmentation with He) favoring isolation and fragmentation of doubly 
charged ions. 
The ESI/MS system was operated with the Xcalibur software (version 2.0, 
ThermoFinnigan), with the same software used also for data analysis.  The mass spectrometer 
was set to function in the positive ion mode with parameters optimized during direct infusion of 
peptide standards with solvent. The solvent, consisting of 50/50 (v/v) 0.1% acetic acid in 
water/acetonitrile, was applied at a flow rate of 3 µL/min.  Nitrogen was used as the sheath gas 
(setting at 60), and ultrapure helium was used as the collision gas.  The ion spray voltage was set 
as 4.5 kV and the capillary temperature was 210°C. 
 
 
Results and Discussion: 
C-peptide, once thought to be an inactive peptide merely existing to help in the folding of 
insulin, could actually have a more active role in the body. Little is known of the active function 
of this peptide in the body, but evidence suggests it has a reason to remain in the body because it 
is not degraded immediately after the formation of mature insulin is complete.  In fact, C-peptide 
has a longer half-life in the body than insulin. Previous studies have attempted to identify 
molecules and proteins that can bind to C-peptide, but they have not found substantial results. 
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This experiment was designed to gain an improved understanding of the cellular actions of C-
peptide by examining what proteins a C-peptide affinity column would extract from three 
different mouse tissue lysates of heart, kidney and liver. Kidney tissue was chosen because the 
clinical data obtained from C-peptide replacement therapy showed that C-peptide ameliorated 
diabetic nephropathy indicating that C-peptide may protect the kidneys from damage caused by 
hyperglycemia.  The kidney was our main tissue of interest, but we also decided to study heart 
tissue because C-peptide is correlated with cardiovascular disorders. We also chose to study liver 
tissue because the liver is the main target organ of mature insulin. 
 
 
Figure 2.6. Basic experimental protocol for protein isolation using the C-peptide affinity beads. 
 
The basic protocol for this experiment is summarized in Figure 2.6. We developed C-
peptide affinity beads by attaching C-Peptide via its N-terminus to the NHS magnetic beads. We 
then lysed heart, kidney and liver mouse tissues and incubated pre-cleared cellular lysates with 
the affinity beads for 3 h at room temperature. Proteins isolated from the affinity beads were 
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separated by reducing SDS-PAGE, digested with trypsin, and analyzed via MALDI-TOF mass 
spectrometry.  
The proteins bands excised from the SDS-PAGE gels were identified by mass 
spectrometry through the Peptide Mass Fingerprint (PMF) technique. In PMF, an unknown 
protein is cleaved into smaller peptide fragments using a specific protease, most commonly 
trypsin.  The molecular weight of each fragment peptide is then accurately measured by mass 
spectrometry. These peptide masses are then compared to a computer database of known protein 
sequences. Mascot, a computer program, works to take the unknown sequence from the database 
and compares them with the masses in order to determine a protein match. In this experiment, the 
proteins isolated were identified via excising a protein band from the gel, digesting the protein 
with trypsin, and analyzing the resulting peptide fragments with MALDI-TOF mass 
spectrometry. 
 
Results from Trial 1 Using Tris Pre-clear Beads: 
The experiment described above was conducted using Tris pre-clear beads and C-peptide 
beads to isolate proteins from both mouse kidney and liver tissue.  The SDS-PAGE gel of the 
isolated proteins can be seen in Figure 2.7. Lane E contained the molecular weight standard 
while A and B contained mouse kidney pre-clear and C-peptide, respectively, and lanes C and D 
contained mouse liver pre-clear and C-peptide, respectively.  
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Figure 2.7. SDS-PAGE Gel separation of proteins.  Lanes: A. Mouse Kidney Lysate pre-clear, 
B. Mouse Kidney Lysate C-peptide, C. Mouse Liver Lysate pre-clear, D. Mouse Liver Lysate C-
peptide and E. molecular weight standards.  
 
 
Proteins Isolated from Kidney Tissue by C-peptide Beads: 
The MALDI-TOF mass spectrum generated from the tryptic digest of the protein at about 
25 kDa in lane B of the SDS PAGE gel (in figure 2.7) is shown in Figure 2.8. The protein band 
had no counterpart protein present in the pre-clear control lane.  This protein was identified as 
the dihydrolipoyllysine-residue acetyl transferase component (E2) of pyruvate dehydrogenase. 
250 kDa 
150 kDa 
100 kDa 
75 kDa 
50 kDa 
37 kDa 
25 kDa 
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The same area was excised from the pre-clear lane, and no peptide fragments were observed as 
expected that indicated that this protein was specifically isolated by the C-peptide beads only.  
This protein has a molecular weight of 67.9 kDa that does not match up with the approximate 25 
kDa position in the gel.  This discrepancy needed to be investigated further.  When the observed 
tryptic peptides are examined, they all originate from the C-terminal portion of the protein as 
shown in Figure 2.9. This suggests that we are isolating a truncated form of this protein that 
originates from either a proteolytic cleavage or through alternate splicing of the protein 
(isoform). Pyruvate dehydrogenase is actually an enzyme complex that catalyzes the overall 
conversion of pyruvate to acetyl-CoA and CO2.  The complex contains multiple copies of three 
enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) 
and lipoamide dehydrogenase (E3).  When activity of the E2 protein is examined, it reveals that 
the N-terminus portion contains the E1 and E3 component binding domains for attachment of E2 
to the pyruvate dehydrogenase complex.  The C-terminal potion of E2 contains the enzymatic 
activity of the protein. E2 utilizes a transacetylation reaction that transfers an acetyl group to the 
thiol in Coenzyme A thus forming acetyl-CoA. The reaction schematic can be seen in Figure 
2.10. Perhaps a truncated version of this protein would produce an enzyme independent of the 
pyruvate dehydrogenase complex that would be able to perform transacetylations on other 
molecules.   We could find no previous research about known alternative splicing variants of this 
protein.   
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Figure 2.8. MALDI-TOF peptide fingerprint mass spectrum for the protein excised from the 
band at 25 kDa in the C-peptide lane of the SDS-PAGE gel for mouse kidney in Lane B of 
Figure 2.7. 
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Figure 2.9. The amino acid sequence of the dihydrolipoyllysine-residue acetyl transferase 
component (E2) of pyruvate dehydrogenase protein.  The peptide sequences observed in the 
mass fingerprint spectrum (Figure 2.8) are shown in red. 
 
 
 
Figure 2.10. Schematic of oxidation decarboxylation of pyruvate as catalyzed by the pyruvated 
dehydrgoenase complex. Reaction C is catalyzed by the dihydrolipoyllysine-residue acetyl 
transferase component (E2). 
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The band excised from the 40 kDa position in lane B of the SDS-PAGE gel for mouse 
kidney C-peptide (Lane B in Figure 2.7) was identified as long-chain specific acyl-CoA 
dehydrogenase (ACADL). The MALDI-TOF mass spectrum generated from the tryptic digest of 
this protein is shown in Figure 2.11.  ACADL is an oxidoreductase enzyme that catalyzes the 
reaction of the reduction of an acceptor using acyl-CoA to 2,3-dehydroacyl-CoA (reaction is 
shown in Figure 2.12). Its primary purpose is in mitochondrial fatty-acid beta-oxidation and lipid 
metabolism.  
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Figure 2.11. MALDI-TOF peptide fingerprint mass spectrum for the protein excised from the 
protein band at 50 kDa in the C-peptide lane of the SDS-PAGE gel for mouse kidney in Lane B 
of Figure 2.7. 
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Figure 2.12. Basic reaction catalyzed by long-chain specific acyl-CoA dehydrogenase. 
 
Proteins Isolated from Liver Tissue by C-peptide Beads: 
The MADLI-TOF mass spectrum generated from the tryptic digest of the protein excised 
from the band at 50 kDa in the C-peptide experimental lane D for mouse liver (Figure 2.7) is 
shown in Figure 2.13. The peptide mass fingerprint search using Mascot identified this protein as 
aldehyde dehydrogenase 2, ALDH2. This protein was not found in the control pre-clear lane, 
indicating that it was a unique protein that was only isolated with the C-peptide beads.  The 
ALDH2 enzyme, localized inside the mitochondrial matrix, can oxidize reactive aldehydes into 
non-reactive carboxylic acids. Because aldehydes are highly reactive molecules in the body they 
act as intermediates or products involved in a wide area of biologic, physiologic and 
pharmacologic processes. In general, aldehydes are created during the metabolism and synthesis 
of amino acids, lipids, carbohydrates and drugs and during the biosynthesis of retinoic acid. 
ALDH2 plays a critical role in the process of detoxification of the products of lipid peroxidation, 
even though it is typically known for its role in the metabolism of alcohols. Evidence suggests 
ALDH2 can protect against both microvasculature and microvasculature against reactive 
aldehydes created in situations of oxidative stress on a system,20 that can  be connected to 
neuropathy and retinopathay associated with diabetes. There are also several human diseases that 
ALDH2 dysfunction may have a role in causing including cardiovascular disease, diabetes, 
neurodegenerative diseases, stroke and cancer.21 It has been shown that ALDH2 expression is 
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dramatically decreased with the progression of diabetes, while the activation of ALDH2 with 
ethanol can decrease diabetes induced myocardial injury.22 C-peptide binding to ALDH2 may 
result in an effect in its activity. Alternatively, it could be entering the nucleus in cells and 
affecting the expression levels of ALDH2, so future work could be to determine the mRNA 
levels of ALDH2 produced when cultured cells are exposed to C-Peptide, that could lead to a 
decrease in activation of ALDH2 and an increase in concentrations of damaging reactive oxygen 
species (ROS) within the cells. An increase in ROS production has been shown to be a mediator 
of hyperglycemic tissue injury. 23 
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Figure 2.13.  MALDI-TOF peptide fingerprint mass spectrum for the protein excised from the 
band at 50 kDa in the C-peptide lane of the SDS-PAGE gel for mouse liver in Lane D of Figure 
2.7.  
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 The MALDI-TOF mass spectrum shown in Figure 2.14 is the tryptic digest for the band 
excised at 100 kDa in the C-peptide experimental lane D for mouse liver of the SDS-PAGE gel 
(Figure 2.7).  The protein was identified via peptide mass fingerprint database search using the 
Mascot search engine to be the major vault protein, MVP. This protein has no corresponding 
band in the pre-clear control lane, indicating it is unique to C-peptide binding. Very little 
information is known about the biological function of vaults. They are composed of mostly MVP 
subunits by mass, and have an evolutionarily conserved amino acid sequence. They are related to 
chemotherapy resistance, transport mechanisms in the cell, signal transduction, and immune 
response. 24 Because so little is known about this protein, conclusions involving its relationship 
with c-peptide would be purely speculation. It could be involved with cell transport of the 
peptide throughout the cytosol of cells, and it could assist with the movement of the C-peptide 
into the nucleus of cells.  
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Figure 2.14.  MALDI-TOF peptide fingerprint mass spectrum for the protein excised from the 
band at 100 kDa in the c-peptide liver lane (D) of the SDS-PAGE gel shown in Figure 2.7.   
 
Results from Trial 2 using Bradykinin Pre-clear Beads: 
The previous experiment was repeated, and the only change was the use of bradykinin 
pre-clear beads in place of the regular Tris pre-clear beads.  This was done in hopes to rule out 
any interaction that is the result of non-specific binding between a peptide and a protein. 
Bradykinin (pictured in Figure 2.15) was a good choice for this substitution, at nine amino acids 
in length; it contains a pair of arginines that are typically positively charged at pH 7.4 and polar 
and hydrophobic amino acids.  It does lack acidic residues that would have been helpful for 
ruling out any electrostatic interactions based upon binding to negative regions on our C-peptide.  
Ideally, we wanted to use a scrambled C-peptide sequence to create the pre-clear beads, but 
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funds were not available to purchase this peptide.  Bradykinin is a bioactive peptide whose 
interactions are known to primarily affect blood vessels, and have no known interactions with 
any of the tissue types worked with during the course of this experiment. Again, mouse kidney, 
heart, and liver tissues were lysed, the lysates were pre-cleared with bradykinin beads, and the 
proteins were then isolated with the same C-peptide beads used in the first experiment.  The 
isolated proteins were eluted from the beads, separated by SDS-PAGE electrophoresis, and 
visualized with Coomassie stain.  The resultant SDS-PAGE gel is shown in Figure 2.16.  Lane C 
of the gel contained molecular weight markers. Lanes A and B came from mouse kidney lysate, 
with A being the pre-clear bradykinin beads and B being the C-peptide beads. Lanes D and E 
came from the mouse heart lysate with D being the pre-clear bradykinin beads and E being the 
C-peptide. Lanes F and G came from the mouse liver lysate with F being the pre-clear 
bradykinin and G being the C-peptide beads. Several protein bands appeared in each lane, and a 
total of 16 of the protein bands were excised and further analyzed by mass spectrometry.  There 
were no bands observed in the heart lysates that differed between the C-peptide and pre-clear 
lanes in the gel, so no proteins bands from the heart lysates were analyzed further.    
 
 
Figure 2.15. The amino acid structure of the peptide Bradykinin.  Amino acid sequence: Arg-
Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg 
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Figure 2.16. SDS-PAGE Gel separation of proteins, Lanes: A. Mouse Kidney Bradykinin Pre-
clear, B. Mouse Kidney C-Peptide, C. Molecular weight standard, D. Mouse Heart Bradykinin 
Pre-Clear, E. Mouse Heart C-Peptide, F. Mouse Liver Bradykinin pre-clear, G. Mouse Liver C-
Peptide. Protein bands were excised from the gel for further analysis.  
 
 
Proteins Isolated from Liver Tissue by C-peptide Beads: 
 The protein bands at about 50 kDa liver lanes were excised and identified via peptide mass 
fingerprint. The protein from both lanes was identified as ALDH2. Figure 2.17 shows the mass 
spectra obtained from the tryptic peptides generated from the protein in the C-peptide lane and 
bradykinin lane. Several of the peptide peaks match up. Pulling out ALDH2 in the bradykinin 
control lane as well as the C-peptide lane suggests that it is a simple matter of peptide 
interactions that ALDH2 would bind to C-peptide. The quality of the spectra is increased in the 
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pre-clear bradykinin lane which makes sense considering the procedure in that the bradykinin 
beads get a chance to bind in the lysate first.  It is for this reason that we believe C-peptide’s 
interactions with ALDH2 is the result of nonspecific peptide binding. 
 
Figure 2.17. MALDI-TOF peptide fingerprint mass spectra for the protein excised from the band 
at 50 kDa in the C-peptide (1.) and bradykinin (2.) lanes of the SDS-PAGE gel for mouse liver in 
Lane G and F, respectively, shown in Figure 2.16. 
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Proteins Isolated from Kidney Tissue by C-peptide Beads: 
The MALDI-TOF mass spectrum shown in Figure 2.18 is the tryptic digest for the protein 
band excised at 40 kDa in the C-peptide experimental lane B for mouse kidney of the SDS-
PAGE gel (Figure 2.16).  The protein was identified via peptide mass fingerprint database search 
using the Mascot search engine to be long-chain specific acyl-CoA dehydrogenase (ACADL).  
The spectrum was not as good as that obtained in the first trial, but there were enough peptide 
peaks to successfully identify the protein.  The fact that we were able to isolate this same protein 
from the kidney lysate with our C-peptide beads strengthens our findings that this protein is a 
cellular target of the C-peptide.  Our only concern is that we would have expected to isolate this 
protein from other tissue lysates, so more work will need to be done to look into why we only 
seem to pull out this protein from the kidney lysates.  
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Figure 2.18. MALDI-TOF peptide fingerprint mass spectrum for the protein excised from the 
band at 40 kDa in the C-peptide lane of the SDS-PAGE gel for mouse kidney in Lane B (Figure 
2.16). 
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The peptide mass fingerprint spectrum obtained for the protein band excised at 25 kDa in 
the C-peptide experimental lane B for mouse kidney of the SDS-PAGE gel (Figure 2.16) is 
shown in Figure 2.19. The protein was identified as dihydrolipoyllysine-residue acetyltransferase 
(E2) component of pyruvate dehydrogenase complex for a second time, with a higher mascot 
score of 87. The gel had no corresponding band in the bradykinin lane A (as seen in Figure 2.16), 
suggesting this is a specific binding for C-peptide. Once again when the peptides observed in the 
spectrum were matched up with the known amino acid sequence of this protein (Figure 2.20), the 
observed peptides were only from the C-terminal portion of the protein, suggesting an 
alternatively spliced protein or a cleaved protein. The repeat identification of this protein with no 
counterpart in the control lane suggests it is a good binding partner for C-peptide. Its appearance 
in the 25kDa position of the gel and the repeat incidence of the peptides matching to the C-
terminus suggests a more purposeful reason for the smaller protein fragment.  To confirm the 
identity of this protein, we sequenced the peptide at m/z 1839 by tandem mass spectrometry. The 
resulting CID MS/MS mass spectrum for the fragmentation of this peptide is shown in Figure 
2.21. Analysis of the y and b fragment ions observed in the CID spectrum revealed that this 
peptide had a sequence consisting of VAPAPAGVFTDIPISNIR that corresponded to the correct 
peptide sequence for the E2 protein.   
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Figure 2.19. MALDI-TOF peptide fingerprint mass spectrum for the protein excised from the 
band at 25 kDa in the c-peptide lane of the SDS-PAGE gel for mouse kidney in Lane B. 
 
 
Figure 2.20. The Matrix Mascot search results for the matched peptide sequences found for the 
peptide peaks observed in Figure 2.19. 
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Figure 2.21. CID mass spectrum recorded on the (M+2H)+2 ion at m/z 919.  The sequence of the 
peptide is shown with the predicted y and b fragments.  Ions observed in the spectrum are 
underlined. 
 
A lot of the previous studies with C-peptide have identified an effect on the Na+K+-
ATPase activity of a cell.  The Na+K+-ATPase is inactive in its phosphorylated state and only 
becomes activated when the phosphate group is removed by a phosphatase enzyme (see Figure 
2.4). The phosphatase enzyme contains a cysteine residue in its active sites that is susceptible to 
oxidation and can serve as a redox sensor for a cell.  In an oxidative environment, this cysteine 
can become oxidized, rendering the phosphatase inactive and preventing the activation of the 
Na+K+-ATPase.  The dihydrolipoyllysine-residue acetyltransferase (E2) has lipoic acid groups 
attached to select lysine residues through an amide bond (Figure 2.22).  In future experiments, 
we plan on isolating more of this protein to confirm the presence of lipoyl groups attached to the 
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protein and to identify which lysine residues within the protein are modified with a lipoyl group.  
Lipoic acid can be synthesized from octanoic acid.  The octanoic acid is already bound to 
enzyme complexes prior to the insertion of the sulfur atoms, so no biologically synthesized lipoic 
acid would be found in a “free” state in cells.  Lipoic acid is a known antioxidant that protects 
cells against damage.  A few studies have suggested that alpha-lipoic acid supplements may 
enhance the body's ability to use its own insulin to lower blood sugar in people with Type-2 
diabetes and may help to reduce the symptoms of peripheral neuropathy.  Hyperglycemia-
induced oxidative stress induces programmed cell death of nerves, that contributes to the 
pathology of diabetic neuropathy.25 Lipoic acid was also shown to increase the amount of 
intracellular glutathione (GSH)26 and has been shown to be a powerful free radical scavenger.   
As diabetes has been associated with increased production and/or decreased clearance of ROS, 
oxidative stress has been suggested to contribute to oxidative damage leading to the 
complications associated with diabetes.  Therefore, the lipoyl groups attached to the E2 protein 
may play an important role in reducing the level of ROS within a cell.  Our experimental results 
have led us to hypothesize that the C-terminal isoform of the E2 enzyme may have an 
antioxidant role in protecting tissues with higher exposure to oxidizing agents like the kidneys 
and that the C-peptide may activate these antioxidant properties of the E2 protein by perhaps 
binding and causing a conformational change that further exposes the lipoyl groups attached to 
the protein.  Further research will need to be conducted to prove this hypothesis.  
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Figure 2.22.  Structure of lipoic acid and its attachment to a lysine residue through an amide 
bond. 
71 
 
 
References: 
1. Steiner, D.F., Cunningham, D., Spigelman, L., and Aten B. (1967).  Science. 157 (3789), 
697–700. 
2. Marques, R.G., Fontaine, M.J., and Rogers J. (2004). Pancreas. 29(3),231-8. 
3. Kim, C.S., Nam, J.H., Nam, J.S., et al. (2006) Metabolism. 55(8),1107-12. 
4. Shiraj, E., Reddy, S., Scherbaum, W.A.,  Abdulkadir, J., Hammel, J.P., and Faiman C.  
(2002). Diabetes Care. 25,453-57. 
5. Wahren,  J., et al. (2000 ) Am J Physiol Endocrinol Metab. 278(5),E759-68 
6. Ido Y, et al. (1997 ) Science. 277(5325),563-6 
7. Rigler. R, et al. (1999) Proc Natl Acad Sci U S A. 96(23),13318-23. 
8. Lebherz, Corinna, and Marx, N. (2013)  Curr Atheroscler Rep 15,339 1-9.  
9. Panero, F., Novelli, G., and Zucco, C. (2009). Diabetes Care. 32,301 
10. Johansson, B.L., Wahren, .J, and Pernow, J.(2003) Am J Physiol Endocrinol Metab. 
285,E864-70 
11. Ekberg, K., Brismar, T., and Johansson, B.L. (2007) Diabetes Care. 30,71–6 
12. Johansson, B.L., Borg, K., and Fernqvist-Forbes, E. (2000) Diabet Med. 17,181–9 
13. Patel, N., Taveira, T.H., and Choudhary, G.(2012)  J Am Heart Assoc. 1,e003152. 
14. Sari, R., and Balci, M.K.(2005). J Natl Med Assoc.5,97,1113–8. 
15. Irwin, M.L., Duggan, C., and Wang, C.Y.(2011) J Clin Oncol.29,47–53. 
16. Bhatt, M.P., Lim, Y.C., and Hwang, J.(2013) Diabetes.62,243–53 
17. Shafqat, J., Melles, E., Sigmundsson, K. et al. (2006) Cellular and Molecular Life Sciences 
.63,1805-11.  
72 
 
18.  Lindahl, E., Nyman, U. , Melles, E., Sigmundesson, K., and Stahlberg., M.  (2007) Cellular 
and Molecular Life Sciences 64,479-86. 
19. Kennedy, R.T.,  and Jorgensen, J.W.(1989) Analyt. Chem. 61, 1128-1135.  
20. Morita, K., Saruwatari, J., Miyagawa, H., et al. (2013) Cardiovasc. Diabetol.  12, 132. 
21. Chen, C.H., Ferreira, J.C., Gross, E.R., and Mochly-Rosen, D.  (2014) Physiol. Rev.  94, 1-
34. 
22. Gao, Q.,Wang, H.J.; Wang, X.M., et. al (2013) Food and Chemical Toxicology  56, 419-424. 
23. Ha, H., Hwang, I., Park, J.H., and Lee, H.B.(2008)  Diabet Res Clin Pract  82, 42-45. 
24. Lara, P.C., Pruschy, M., Zimmerman, M., and Hernandez, L.A.  (2011) Radiat Oncol. 6, 148. 
25. Zimmer, G. In: Fuchs, J., Packer, L., Zimmer, G., editors. (1997)Lipoic acid in health and 
disease. 67–86. 
26. Busse, E., Zimmer, G., Schopohl, B., Kornhuber, B. and Arzneimittelforschung. 
(1992)42,829–831 
 
 
 
 
 
 
 
73 
 
 
Appendix A: 
Results from Earlier Trials for Heart Tissue Lysates: 
In an early trial, an alternative form of C-peptide that still contained the RR and KR 
amino acids on the termini of the peptide was used to generate the C-peptide beads.  This peptide 
was chosen in the hope that the extra primary amine in the additional lysine residue would bind 
to the NHS beads, leading to binding at both ends of the peptide as opposed to only through the 
N-terminus. Mouse heart, liver, and kidney tissue was lysed with NP-40 lysis buffer, pre-cleared 
with Tris beads, and incubated with C-peptide beads overnight at 4° C.  The isolated proteins 
were then separated by SDS-PAGE electrophoresis (Figure A.1).  For this trial, the kidney and 
liver lanes of the gel were too overloaded to identify any protein binding partners, but the mouse 
heart lane had several proteins that could be identified via Peptide Mass Fingerprint.  
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Figure A.1. SDS-PAGE gel of proteins isolated with C-peptide beads from mouse heart lysate, 
mouse kidney lysate, and mouse liver lysate.  Protein bands from the heart lane were excised 
from the gel for further analysis. 
 
The protein band at about 55 kDa was excised from gel, digested with trypsin, and 
analyzed by MALDI-TOF mass spectrometry (Figure A.2).  The protein was identified as ATP 
synthase subunit alpha.  The purpose of this protein is to produce ATP from ADP in complex V 
in the electron transport chain using a proton gradient across the membrane that is generated by 
electron transport complexes of the respiratory chain. Unfortunately, this protein was found in 
subsequent trials using the NHS magnetic beads in the pre-clear lanes, indicating it has an 
affinity for the NHS beads themselves and not C-peptide. 
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Figure A.2. MALDI-TOF peptide fingerprint mass spectrum for the protein excised from the 
band at 55 kDa in the heart lysate lane in the SDS-PAGE gel in Figure A.1.  
  
The protein band at about 30 kDa was also excised from gel, digested with trypsin, and 
analyzed by MALDI-TOF mass spectrometry (Figure A.3).  The protein was identified as 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  This enzyme catalyzes the sixth step in 
glycolysis, serving to breakdown glucose for energy, specifically the reaction of glyceraldehyde 
3-phosphate to D-glycerate 1,3-bisphosphate (Figure A.4).  C-peptide may bind to GAPDH to 
help activate the break down of glucose. This would make sense since insulin and C-peptide are 
released from the pancreas when blood glucose levels are high.  Throughout our C-peptide trials, 
we isolated this protein once again from liver tissue, and we never identified this protein from 
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any pre-clear samples.  This protein remains a good candidate as an effector protein of the C-
peptide; however, additional trials need to be conducted to confirm this result. 
 
 
 
 
Figure A.3. MALDI-TOF peptide fingerprint mass spectrum for the protein excised from the 
band at 30 kDa in the heart lysate lane in the SDS-PAGE gel in Figure A.1. 
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Figure A.4. The reaction catalyzed by GAPDH as part of the glycolysis cycle. 
 
 
